Navigation Links
DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
Date:9/17/2013

New York, NY (PRWEB) September 17, 2013

The diabetes drug resource center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. A federal panel recently consolidated a growing number of lawsuits alleging the drug caused cancer to a multidistrict litigation court for expedited handling*.

DrugRisk seeks to improve patient safety by providing the latest recalls, safety alerts, research and litigation news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a popular injectable medication prescribed to those with type-II diabetes to lower blood sugar levels. However, the resource center has added information showing experts disagree about its safety.

In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer**. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

The Institute for Safe Medication Practices has attributed a majority of serious diabetes drug side effect reports to the FDA to Byetta****. However, the FDA has not issued a recall or required new warning labels.

Now, DrugRisk has learned that, due to the growing number of patients who have filed a Byetta lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation has consolidated cases to a special multidistrict litigation federal court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California)*.

Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have already handled these complex Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 8/26/13; jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****ISMP QuarterWatch April, 2013.ismp.org/QuarterWatch/pdfs/2012Q3.pdf

Read the full story at http://www.prweb.com/releases/byetta-pancreatic-thyroid/cancer-symptoms/prweb11130048.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
2. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
3. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
4. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
5. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
6. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
7. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
8. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
9. DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
10. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
11. DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... My T Chai, ... its products are now available for purchase on RevNutrition.com, a popular website specializing in ... first produced and popularized in ancient India and Siam. It spread across Asia and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... 24, 2017 , ... In 2017, up to 78,000 new ... of them will be malignant.(1) As research into precision medicine continues, both patients ... in the diagnosis and treatment of brain tumors. Healthcare facilities that are already ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: